Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma
NCT07413354
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
94
Enrollment
OTHER
Sponsor class
Conditions
Hepatocellular Carcinoma (HCC)
Interventions
DRUG:
Tislelizumab plus Huaier granule
Sponsor
Tongji Hospital